Objective: To evaluate the efficacy and safety of Anlotinib as a third-line therapy in patients with metastatic colorectal cancer. Methods: Anlotinib was administered to patients with advanced colorectal cancer who had received ≥ second-line standardized treatment, with 12 mg daily lasting for 2 weeks and withdrawal of drugs for a week. The relevant clinical information and treatment protocols were recorded.The efficacy and safety of anlotinib were followed up. Results: A total of 26 patients were enrolled in the study group, and 24 patients could be evaluated, including 2 cases of partial response (PR) and 16 cases of stable disease (SD).The object response rate (ORR) and disease control rate (DCR) were 8.3% and 75%, respectively. The median progression-free survival (PFS) and overall survival (OS) was 4.3 months (95% CI: 2.9-5.7 months) and 14.7 months (95% CI: 10.0-19.4 months), respectively. The most common adverse reactions were fatigue in 17 cases (17/26) and hand-foot skin reactions in 16 cases (16/26). Analysis of Kaplan-Meier revealed that without liver metastasis (95% CI: 11.7-32.3, P=0.011) and left-sided colonic cancer (95% CI: 11.7-46.1, P=0.014) were related to longer OS. Conclusion: Anlotinib as a third-line therapy for advanced colorectal cancer is feasible with high disease control rate and minor side effects.
目的： 观察盐酸安罗替尼胶囊用于晚期转移性结直肠癌患者的临床疗效和安全性。 方法： 选择2016年1月至2018年8月安徽医科大学第二附属医院肿瘤内科收治的既往曾接受过≥二线标准化疗的晚期结直肠癌患者，给予盐酸安罗替尼胶囊，1次/d，每次12 mg，连续用药2周停1周。记录相关临床信息、治疗方案并随访疗效和安全性，分析预后影响因素。 结果： 共入组26例患者，可评效24例，部分缓解（PR）2例，疾病稳定（SD）16例，疾病控制率（DCR）为75%。中位无进展生存时间（PFS）为4.3个月（95% CI: 2.9~5.7个月），中位总生存时间（OS）为14.7个月（95% CI: 10.0~19.4个月）；最常见不良反应为乏力17例（17/26）和手足皮肤反应16例（16/26）；采用Kaplan-Meier法绘制生存曲线并行Log-rank检验，无肝转移患者（95% CI: 11.7~32.3，P=0.011）、左半结肠（95%CI：11.7~46.1，P=0.014）与较长的OS有关。 结论： 盐酸安罗替尼三线及后线治疗晚期结直肠癌的近期疾病控制率较高，不良反应可耐受。.
Keywords: Anlotinib; Clinical effects; Metastatic colorectal cancer; Targeted therapy.